| Company: | Amedisys Inc, |
| Ticker Symbol: | AMED |
| Class Period: | Feb-23-10 to May-13-10 |
| Date Filed: | Jun-15-10 |
| Lead Plaintiff Deadline: | Aug-14-10 |
| Court: | Middle District of Louisiana |
| Allegations: | |
The Complaint charges that Amedisys and certain of its officers and executives violated federal securities laws. Specifically, the Complaint alleges that defendants made misleading statements and/or failed to disclose: (i) that the Company's reported sales and earnings growth were materially impacted by a scheme whereby the Company intentionally increased the number of in-home therapy visits to patients for the purpose of triggering higher reimbursement rates under the Medicare home health prospective payment system, as those excess visits were not always medically necessary; (ii) that the Company's reported sales and earnings were inflated by said scheme and subject to recoupment by Medicare; and (iii) that the Company was in material violation of its Code of Ethical Business Conduct and compliance due to the scheme to inflate Medicare revenues.
On May 13, 2010, The Wall Street Journal reported that the Senate Finance Committee had started an investigation into the billing and operating practices of Amedisys. On this news, Amedisys stock fell $4.48 per share.
If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.
